Adam Adler

Adam Adler has a diverse work experience in the field of scientific research and development. Adam began their career as a Postdoctoral Fellow at Stanford University School of Medicine in 2008 and later joined Genentech as a Senior Scientific Researcher in 2009. In 2012, Adam joined LakePharma, Inc. as a Director of Research Collaborations and Senior Scientist. Adam then transitioned to GigaGen Inc in 2014, where they held the positions of Director of Research and Development, Vice President of Research and Development, and finally, Chief Scientific Officer. Alongside their work at GigaGen, Adam co-founded GigaMune in 2017, a company focused on advancing T cell therapies for cancer and developing personalized polyclonal TCR cell therapies. Overall, Adam's work experience showcases their expertise in scientific research and leading roles in the biotechnology industry.

Adam Adler received their Bachelor of Arts degree in Biological Sciences from Northwestern University, where they studied from 2000 to 2004. Adam then pursued further education at Stanford University School of Medicine, where they earned their Ph.D. in Cancer Biology. Adam attended Stanford from 2004 to 2008.